DxPx Conference on November 17th With Investors From Over 20 Countries

International partnering conference for diagnostics, regenerative medicine and research tools with an extensive online and offline program

DUSSELDORF, Germany – As Europe’s largest international partnering conference for diagnostics, digital health, regenerative medicine and research tool industry, DxPx 2020 offers an ideal network platform for startups, companies and investors. This year it will take place initially in a hybrid form; analog and digital. The participants have the opportunity to attend pre-scheduled one-on-one meetings with more than 150 active investors as well as to join panel discussions with leading representatives of family offices, venture capital and private equity companies.

From all across the globe, after registration, participation via smartphone, tablet or computer and thus without exposing yourself to the health risk of infection with the corona virus, is possible to evaluate investment opportunities, M&A and license options and R&D partnerships between entrepreneurs and investors.

DxPx is sponsored by partners such as Roche Diagnostics, Euroimmun, MyBioGates, the US investment bank Brown Gibbons Lang and company builder SilverSky LifeSciences. Besides participating at partnering and panel discussions selected companies also have the opportunity to present themselves at the China-forum to investors from the People’s Republic of China such as Fosun Pharma and Goldman Sachs. After more than 400 participants last year, DxPx has the prospect of more active investors focusing on diagnostics, precision medicine and research tools than any other partnering conference.

“We want to promote an intensive exchange between newcomers and established companies, and we look forward to further applications. In addition to digital participation in panels, the possibility of one-on-one meetings with speakers or other potential business partners, which can be scheduled in advance, represents an enormous added value of the DxPx for all participants,” says Dr. Mirko Stange, initiator of the DxPx.

More than 30 renowned investors will share their knowledge and experience in the panel discussions. Examples are Lions Head, a fund of the Bill and Melinda Gates Foundation, Capricorn Partners, Illumina Ventures, Earlybird Partners or, with CS Ventures, a corporate investor from New Zealand, focused on diagnostics.

Dr. Bernd Goergen, Partner of the High-Tech Gründerfonds, a sponsor of DxPx since its first inauguration event: „Mankind will benefit more and more from personalized therapies. Being able to deliver highly effect treatments strongly depends on having access to new innovative diagnostic solutions. Partnerships between pharma, biotech and diagnostics will become more valuable and we therefore look forward to this year’s event. We strongly encourage innovative companies to submit their pitch for a chance to be selected for a company presentation slot at DxPx.”

Companies can apply for a live performance and the DxPx Award until October 31.

Journalists can register online via info@dxpx-conference.com.

Social Sharing

Did you like the article? If so, we would be happy if you share it with your friends and acquaintances!

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.